Tezepelumab regulatory submission accepted and granted FDA priority review in the US for the treatment of patients with asthma

AstraZeneca

8 July 2021 - Tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population across Phase 2 and 3 clinical trials.

AstraZeneca’s biologics license application for tezepelumab has been accepted and granted priority review for the treatment of asthma from the US FDA.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Priority review , Dossier